Every 8-K that Tyra Biosciences, Inc. (TYRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TYRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TYRA filings page.
Tyra Biosciences, Inc. (TYRA) reported initial Phase 2 data for oral dabogratinib in the SURF302 study in FGFR3‑altered low-grade intermediate-risk non-muscle invasive bladder cancer, providing clinical proof of concept and supporting 60 mg once-daily as a potential dose for a planned registrational adjuvant strategy. As of the August 31, 2026 cutoff, safety and tolerability were favorable in both 60 mg (n=22) and 50 mg (n=22) cohorts, with most treatment-emergent adverse events Grade 1–2; Grade 3 TEAEs occurred in 3 participants (14%) at 60 mg and 2 (9%) at 50 mg, with no Grade 4 or 5 events and no Grade 3 treatment-related events at 60 mg.
Among 26 efficacy-evaluable participants, the 60 mg cohort showed an overall response rate of 79% (11/14) and a best overall complete response rate of 64% (9/14), while the 50 mg cohort showed an overall response rate of 67% (8/12) and complete response rate of 33% (4/12). In single marker lesions, 60 mg achieved a 100% overall response rate (8/8) at three months, and pooled 50/60 mg dosing achieved 94% (15/16). TYRA highlighted that about 61% of enrolled patients had no prior intravesical therapy and cited third-party research estimating a potential IR NMIBC market opportunity of more than $5 billion. TYRA also noted an initial complete response at three months in the first SURF303 low-grade UTUC patient at 60 mg with no observed TEAEs, and clearance of the fifth dose level without safety signals in the BEACH301 pediatric achondroplasia study’s safety sentinel cohort.
Tyra Biosciences, Inc. reported second quarter 2026 results as a clinical-stage biotechnology company focused on FGFR biology. For the quarter ended June 30, 2026, net loss was $45.6 million, with research and development expenses of $39.2 million and general and administrative expenses of $9.8 million. Net loss per share was $0.69 basic and diluted. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $353.9 million.
Management highlighted its “dabogratinib 3x3” strategy, advancing three Phase 2 trials (SURF303 in LG-UTUC, SURF302 in IR NMIBC and BEACH301 in achondroplasia), with initial SURF302 data expected in September 2026 and BEACH301 safety cohort data by end of first quarter 2027. The safety sentinel cohort in BEACH301 has cleared four dose levels without notable safety events, and a fifth dose level has been opened. Tyra appointed Jonathan Day as Executive Vice President, Clinical Development for skeletal dysplasia conditions and amended its at-the-market equity sales agreement, enabling up to an additional $250.0 million in common stock sales. Current cash resources are expected to fund planned operations into the second half of 2028.
Tyra Biosciences, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 28, 2026. Stockholders elected three directors: Habib J. Dable, Susan Moran, M.D., M.S.C.E., and Robert More. Each nominee received over 41 million votes in favor, with 8,377,977 broker non-votes recorded on each director item.
Stockholders also approved another meeting proposal with 53,092,820 votes for, 1,316 against, and 3,246 abstentions, and no broker non-votes.
Tyra Biosciences reported a first quarter 2026 net loss of $39.3 million, wider than $28.1 million a year earlier, as it increased spending to advance its pipeline. Research and development expenses rose to $33.5 million, driven by Phase 2 trials for oral dabogratinib in urologic cancers and achondroplasia and start-up costs for the SURF303 study.
General and administrative expenses were $8.5 million compared with $6.9 million in 2025, reflecting higher personnel costs. Tyra ended March 31, 2026 with cash, cash equivalents and marketable securities of $383.5 million, which it expects will fund operations into the second half of 2028. The company also issued shares under its at-the-market program and continues to progress multiple Phase 2 studies under its “dabogratinib 3x3” strategy.
Tyra Biosciences, Inc. expanded its board of directors from nine to ten members and appointed Habib J. Dable as a Class II director, with his initial term ending at the company’s 2026 annual meeting of stockholders. The board determined he qualifies as an independent director under Nasdaq rules.
In connection with his appointment, Dable received options to purchase 44,400 shares of Tyra’s common stock at the fair market value on the grant date, vesting in equal monthly installments over 36 months. He will also receive cash compensation under the company’s Non-Employee Director Compensation Program and has entered into Tyra’s standard indemnification agreement.
Tyra Biosciences, Inc. named Julia Rueb, its Vice President of Finance, as the company’s principal accounting officer, effective April 1, 2026. She succeeds Chief Financial Officer Alan Fuhrman in this specific role, while he continues to serve as the company’s principal financial officer.
Rueb, age 40, has been Vice President, Finance since January 2024 and previously held senior accounting and controller roles at the company. Her background includes technical accounting and consulting positions at SOAProjects, van den Boom & Associates, and audit experience at Ernst & Young, primarily serving public life sciences companies.
Tyra Biosciences, Inc. entered into an agreement to issue and sell 4,000,000 shares of common stock to a large investment management firm in a block transaction. The shares are priced at $31.50 per share, and Tyra Biosciences expects to receive $126.0 million in gross proceeds upon settlement, before fees and other expenses.
The transaction is being carried out under the company’s existing “at-the-market” offering program, which is registered on Form S-3 under the Securities Act of 1933. The terms of this program are described in a sales agreement prospectus dated May 16, 2025, with related documents available on the SEC’s website.
Tyra Biosciences reported fourth-quarter and full-year 2025 results and outlined progress on its FGFR-focused pipeline. The company ended 2025 with $256.0 million in cash, cash equivalents and marketable securities and expects this to fund operations through at least 2027.
Research and development expenses rose to $28.2 million in Q4 and $102.9 million for 2025, driven mainly by oral dabogratinib clinical programs, including BEACH301 and SURF302 plus start-up for SURF303. General and administrative costs increased to $8.3 million in Q4 and $29.8 million for the year due to higher headcount-related spending.
Net loss was $33.8 million in Q4 and $119.9 million for 2025 as the company continues to invest in development. Tyra emphasized its “dabogratinib 3x3” strategy, concentrating on three Phase 2 studies in LG-UTUC, IR NMIBC and achondroplasia, with key data readouts expected in 2026.
Tyra Biosciences, Inc. filed an 8-K announcing it issued a press release covering financial results for the quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1.
Consistent with General Instruction B.2, the information in this report, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act. The filing lists the company’s common stock under the symbol TYRA on the Nasdaq Global Select Market.
Tyra Biosciences, Inc. furnished a current report to note that it has issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release, dated August 14, 2025, is included as Exhibit 99.1 to this report and is incorporated by reference. The company specifies that this earnings information, including the exhibit, is being furnished rather than filed, which limits how it is treated under certain liability provisions of U.S. securities laws.